STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours
Histopathology · 2024-11 · 85 (5) · 769-782
DOI: 10.1111/his.15303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 21.08.2024. Verfasst von Amir Dehghani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Immunohistochemistry, AMP-Activated Protein Kinase Kinases, Biomarkers, Tumor, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aims
STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: ‘ ST11 ’ in preceding sentence has been corrected to ‘ STK11 ’ in this version.] It predominantly originates from the para‐adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non‐specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics. Methods and results IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra‐ovarian sex cord‐stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo‐ovarian high‐grade serous carcinomas, five ovarian mesonephric‐like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high‐grade serous carcinoma with subclonal loss.
Conclusions
STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Histopathology, King Edward Memorial Hospital, Perth, WA, Australia.
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Aarti E Sharma, Stephanie E Siegmund, Chrystalle K Carreon, Colin J R Stewart, Jelena Mirkovic, Christopher P Crum, Jason L Hornick, Brooke E Howitt, W Glenn McCluggage, David L Kolin
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Dehghani, A., Sharma, A. E., Siegmund, S. E., Carreon, C. K., Stewart, C. J. R., Medeiros, F., Mirkovic, J., Nucci, M. R., Crum, C. P., Hornick, J. L., Howitt, B. E., McCluggage, W. G., & Kolin, D. L. (2024). STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours. Histopathology, 85(5), 769-782. https://doi.org/10.1111/his.15303
Vancouver
Dehghani A, Sharma AE, Siegmund SE, Carreon CK, Stewart CJR, Medeiros F, et al. STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours. Histopathology. 2024;85(5):769-782. doi:10.1111/his.15303
BibTeX
@article{Dehghani2024,
author = {Dehghani, Amir and Sharma, Aarti E and Siegmund, Stephanie E and Carreon, Chrystalle K and Stewart, Colin J R and Medeiros, Fabiola and Mirkovic, Jelena and Nucci, Marisa R and Crum, Christopher P and Hornick, Jason L and Howitt, Brooke E and McCluggage, W Glenn and Kolin, David L},
title = {STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours},
journal = {Histopathology},
year = {2024},
volume = {85},
number = {5},
pages = {769--782},
doi = {10.1111/his.15303}
}
EUVIMED